Nasopharyngeal carcinoma(NPC)is a squamous cell carcinoma arising from the nasopharyngeal epi-thelium,which is associated with Epstein-Barr virus(EBV)infection and is most common in southern China.Im-munotherapy,particularly immune checkpoint inhibitors(ICIs),provides favorable efficacy with a good safety profile in a variety of solid tumors,including recurrent or metastatic NPC(R/M-NPC).In addition,immuno-therapy has made new breakthroughs in the treatment of locally advanced NPC,and many clinical studies are un-derway.Based on previously reported results,this study presents a comprehensive overview of the advances and challenges by introducing the basic principles and the current status of immunotherapy in NPC,with the expecta-tion that it will serve as a reference for clinical practice in the future.
关键词
程序性细胞死亡受体-1/免疫治疗/临床研究/鼻咽癌
Key words
programmed cell death protein 1/immunotherapy/clinical trial/nasopharyngeal carcinoma
维普
万方数据